Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of ranibizumab in combination with reduced-fluence verteporfin
photodynamic therapy (RF-PDT) in patients with subfoveal choroidal neovascularization
secondary to pathologic myopia (PM).
Phase:
Phase 1
Details
Lead Sponsor:
Second University of Naples University of Campania "Luigi Vanvitelli"